Boston Scientific Corporation

NYSE:BSX Stock Report

Market Cap: US$111.1b

Boston Scientific Past Earnings Performance

Past criteria checks 4/6

Boston Scientific's earnings have been declining at an average annual rate of -23.2%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 7.9% per year. Boston Scientific's return on equity is 8.8%, and it has net margins of 12%.

Key information

-23.2%

Earnings growth rate

-24.3%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate7.9%
Return on equity8.8%
Net Margin12.0%
Next Earnings Update24 Jul 2024

Recent past performance updates

Recent updates

Boston Scientific Q2 Earnings Preview: Can The Rally Continue?

Jul 17

Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Jul 05
Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching

Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Jun 21
Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?

Boston Scientific Has Become A Standout Growth Story In Med-Tech

Jun 13

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Jun 08
Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

May 10
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Apr 22
Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash

Apr 05

A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Mar 26
A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

Feb 29
We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Feb 15
What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Is Boston Scientific (NYSE:BSX) A Risky Investment?

Feb 02
Is Boston Scientific (NYSE:BSX) A Risky Investment?

Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Jan 19
Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Boston Scientific: Portfolio Updates Driving Top-Line Growth

Jan 17

Boston Scientific: Continued M&A Drives More Growth

Jan 10

Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Dec 04
Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Nov 03
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue

Oct 30

ADVENT Offers Up An Early Present For Boston Scientific Investors

Aug 28

Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Aug 24
Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Jul 25
Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Boston Scientific Remains Operationally Sound But May Have Limited Upside

Jul 14

Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Jul 10
Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

May 21
Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Apr 18
Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Apr 03
Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Boston Scientific Stands Out With Strong, Diversified Growth Profile

Feb 15

Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line

Feb 01

Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference

Jan 11

Revenue & Expenses Breakdown

How Boston Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:BSX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2414,7071,7655,3391,443
31 Dec 2314,2401,5705,1901,414
30 Sep 2313,7571,1914,9741,381
30 Jun 2313,4008614,8651,364
31 Mar 2313,0458464,6751,341
31 Dec 2212,6826424,5201,323
30 Sep 2212,5675964,5101,313
30 Jun 2212,3298284,4451,284
31 Mar 2212,1627544,4001,247
31 Dec 2111,8889854,3591,204
30 Sep 2111,4701,1014,1821,166
30 Jun 2111,1965264,0991,171
31 Mar 2110,1222013,7771,115
31 Dec 209,913-1153,7871,143
30 Sep 2010,1083,6853,8641,165
30 Jun 2010,1573,9803,8921,157
31 Mar 2010,7854,2874,0621,194
31 Dec 1910,7354,7003,9281,174
30 Sep 1910,3921,0903,7901,154
30 Jun 1910,0771,3963,6481,136
31 Mar 199,9371,7973,5661,132
31 Dec 189,8231,6713,5571,113
30 Sep 189,6706703,4981,088
30 Jun 189,5005213,4241,053
31 Mar 189,2671123,3501,023
31 Dec 179,0481043,281997
30 Sep 178,8318433,227990
30 Jun 178,7147883,199969
31 Mar 178,5824353,163945
31 Dec 168,3863473,083920
30 Sep 168,095813,029908
30 Jun 167,878-3452,979895
31 Mar 167,595-362,898894
31 Dec 157,477-2392,847876
30 Sep 157,314-3962,819840
30 Jun 157,272-1552,836832
31 Mar 157,302-2532,883818
31 Dec 147,308-1192,878817
30 Sep 147,2582882,849826
30 Jun 147,1472402,766831
31 Mar 147,0833662,680848
31 Dec 137,070-1212,651861
30 Sep 137,126-1682,566882

Quality Earnings: BSX has high quality earnings.

Growing Profit Margin: BSX's current net profit margins (12%) are higher than last year (6.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BSX's earnings have declined by 23.2% per year over the past 5 years.

Accelerating Growth: BSX's earnings growth over the past year (108.6%) exceeds its 5-year average (-23.2% per year).

Earnings vs Industry: BSX earnings growth over the past year (108.6%) exceeded the Medical Equipment industry 5.5%.


Return on Equity

High ROE: BSX's Return on Equity (8.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.